Topic archive

clinical trials

13 stories

9/1/2026

Barrow, ASU launch clinical trial for ibogaine in the US

The study aims to explore ibogaine's potential for treating PTSD and addiction.

8/19/2026

Barrow Neurological Institute to test ibogaine's safety and efficacy in a state-funded trial.

8/19/2026

Ibogaine, a psychedelic drug, gains federal attention for treating addiction.

8/10/2026

Arizona funds first U.S. ibogaine trial for traumatic brain injuries, starting 2027.

8/10/2026

ARPA-H seeks to accelerate ibogaine trials for opioid treatment

8/8/2026

The biotech firm aims for vertical integration in psychedelic therapeutics.

8/7/2026

Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.

8/5/2026

Grant supports research into ibogaine's effects on neurological disorders.

7/29/2026

Psychedelic trials often exclude marginalized groups, raising questions about equity and efficacy.

7/29/2026

Ibogaine HCl aims to treat PTSD, TBI, and opioid use disorder.

7/22/2026

Trump's 2026 executive order boosts psychedelic research funding and collaboration.

7/16/2026

Mayor Gina Ortiz Jones pushes for psychedelic trials to aid veterans.

7/8/2026

Ibogaine remains illegal in the U.S., yet clinical trials are underway.